CymaBay Therapeutics Inc. (CBAY)

NASDAQ: CBAY · IEX Real-Time Price · USD
2.77
-0.18 (-6.10%)
Jul 1, 2022 4:00 PM EDT - Market closed

Company Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis.

The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target.

The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CymaBay Therapeutics Inc.
CymaBay Therapeutics Logo
Country United States
Industry Pharmaceuticals
Sector Health Care
Employees 59
CEO Sujal Shah

Contact Details

Address:
7575 Gateway Blvd Ste 110
Newark, California 94560-1194
United States
Phone 510 293 8800
Website cymabay.com

Stock Details

Ticker Symbol CBAY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001042074
CUSIP Number 23257D103
ISIN Number US23257D1037
Employer ID 94-3103561
SIC Code 2834

Key Executives

Name Position
Sujal A. Shah President, Chief Executive Officer and Director
Dr. Dennis D. Kim M.B.A., M.D., MBA Chief Medical Officer
Lewis J. Stuart B.A., BA, M.B.A., MBA Chief Commercial Officer
Daniel Menold Vice President of Finance
Dr. Charles A. McWherter Ph.D. Senior Vice President and Chief Scientific Officer
Paul T. Quinlan General Counsel, Chief Compliance Officer and Corporate Secretary
Ken Boehm Senior Vice President of Human Resources
Patrick J. O'Mara Senior Vice President of Business Development
Dr. Robert L. Martin Senior Vice President of Manufacturing and Nonclinical Development
Klara A. Dickinson-Eason Chief Regulatory and Quality Assurance Officer

Latest SEC Filings

Date Type Title
Jun 14, 2022 8-K Current report
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Apr 26, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2022 DEF 14A Other definitive proxy statements
Apr 19, 2022 8-K/A Current report
Mar 21, 2022 4 Statement of changes in beneficial ownership of securities
Mar 21, 2022 3 Initial statement of beneficial ownership of securities
Mar 17, 2022 8-K Current report
Mar 17, 2022 S-8 Securities to be offered to employees in employee benefit plans